The company plans to use the proceeds to test its TCR-T cell therapy in patients with MAGE-A4-positive solid tumors.

The recommendation is based on the Phase II/III DEVOTE study testing the higher dose in treatment-naïve patients and those already on the low dose.

The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

SEATTLE – Guidelines for germline genetic testing have changed rapidly in recent years, and community cancer centers are struggling to implement programs that can identify and facilitate testing for ...

The agency is cautioning patients about the risk of serious, possibly fatal, liver injuries and has limited the gene therapy's use to ambulatory patients.

NEW YORK – German biotech ITM Isotope Technologies Munich has submitted a new drug application to the US Food and Drug Administration for its radiopharmaceutical 177Lu-edotreotide as a treatment for ...

NEW YORK – The American College of Medical Genetics and Genomics (ACMG) this week released a clinical practice resource for the management of patients with heterozygous germline pathogenic variants in ...

The agency reviewed data from a Phase II study, in which around 21 percent of patients had a complete response to the menin inhibitor.

NEW YORK – Fondazione Telethon said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for its gene therapy ...